Can DNA tests match more pancreatic cancer patients to the right drugs?

NCT ID NCT05927298

First seen Feb 23, 2026 · Last updated Jun 23, 2026 · Updated 21 times

Summary

This study enrolls 200 people with pancreatic cancer across Ontario. Researchers collect tumor tissue, blood, and stool samples to perform genetic sequencing and grow mini-tumors in the lab. The goal is to see if this detailed analysis helps more patients receive a treatment matched to their cancer's unique features. This is an observational study, so participants receive standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could show that genetic and organoid testing helps more pancreatic cancer patients receive treatments tailored to their tumor.

What could go wrong

This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may take years to influence clinical practice.

Conditions

The condition(s) this trial relates to.

pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.